AI-EXPO
6.6.2018 18:27:09 CEST | Business Wire | Press release
Arriving in Amsterdam on the 27-28 June , the second annual AI Expo Europe event will host 2 co-located events covering IoT and Blockchain , with 8,000 attendees expected to attend including CTO’s, CDO’s, Head’s of Innovation and Technology, IT Directors, Developers & Start-Up’s, OEM’s, Government, Automotive, Operators, Technology Providers, Investors, VCs and many more. The AI Expo will showcase the most cutting-edge technologies from more than 300 exhibitors and provide insight from over 300 speakers sharing their unparalleled industry knowledge and real-life experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180606006061/en/
1. The exhibition and start-up incubator zone
The event will host a dedicated start-up incubator zone where you can see the latest AI & IoT technologies and innovations in action, in addition to the vast exhibition of 300+ companies who will be showcasing their products and services within the field of AI, IoT & Blockchain. Expect to see demos and booths from Microsoft, IBM, PTC, Kore, Hercules, Thales, Rutronik, Enterprise Ethereum Alliance, BPU Holdings, Start-up Amsterdam, ML6, Bottos, Ortec Data Science, Adani, NTR Labs, Prosper BI and many more. Start-ups within the incubator zone include Aiir Innovations, Botsquad, Mercury.AI, IoTify, Porter, 3D Universium, Zazu, 904 Labs, Innovation in Motion, Blockhearts, Mind Trace, Sightcorp, Cupenya, Effect.Ai, Sodaq, Amberscript, BrainCreators, Clockworks to name a few. In addition, attendees can join speakers from Aiir Innovations, Mercury.AI and BrainCreators within the AI Technologies track on day 2 (28th June) as they explore innovative artificial intelligence techniques.
2. 10 Conference Tracks covering AI, IoT and Blockchain
Your Free Expo Pass will provide access to 10 conference tracks; AI Technologies , Data Analytics for AI & IoT, Developing for the IoT , Privacy & Security , IoT Innovations & Technologies , ICOs & Token Investments, Blockchain for Business , Developing Blockchain Applications , Blockchain Technologies and Blockchain Strategies. Register for your free expo pass here.
3. Keynote Panel: IoT and AI data analytics for intelligent decision making
Taking place on the 27th June at 10.15am within the Data Analytics for AI & IoT conference track, the Chief Data Scientist at Southern Water , a Data Scientist from Monsanto, a Data Scientist from Marel Poulty and the CEO from the predictive intelligence firm Prosper BI will be identifying target-rich, high-value data that can be used to generate business intelligence, looking at the use of cloud analytics platforms to derive value from AI & IoT data, and discussing the barriers to widespread AI/IoT/Big Data value delivery and how these might be overcome.
4. Machine Learning and AI: Do’s and Don’ts in the online food provider industry
Adrian Foltyn, Former Head/Director of Data Science at HelloFresh, the online food survival kit provider, will take to the stage within the Data & Analytics for AI & IoT track on the 27 June at 15.20pm. Adrian will discuss why preference data is at the core of the company’s operations as their predictive technologies forecast the food that their consumers want during certain seasons.
5. AI and Computer Vision – Intelligent Assistants and an extra pair of eyes…
Join Miriam Huijser, Co-Founder & Chief Research Officer at Aiir Innovations on 28 June within the AI Technologies conference track as she explores how intelligence assistants can be used to inspect aircraft engines using state-of-the-art computer vision techniques. Aiir Innovations is an Amsterdam based start-up that aims to bring artificial intelligence to the maintenance and aircraft industry. They will also be exhibiting within the start-up incubator zone within the expo floor.
6. 2 co-located events
Co-located with the IoT Tech Expo and the Blockchain Expo, the AI Exhibition and Conference will allow you to explore 3 ecosystems in 1 and discover how the convergence of these 3 areas is powering the future of technology!
7. Using Big Data to create intelligent data models
Within the dedicated Data Analytics for AI & IoT track on the 27 June at 14.40pm, join AI & IoT thought leaders as they take to the stage for a panel discussion. Hear from Christophe Eschenbrenner, IoT & Data Foundations Program Manager from Alstom Digital Mobility , Violeta Misheva, Data Scientist at ABN AMRO Bank N.V. , Filippo F.G. Della Casa, Head of Analytics at Unipol and Dor Kedem, Senior Data Scientist at ING as they discuss the increased need for big data analytics to drive AI & Machine Learning across a range of industries.
Other event features include exclusive networking opportunities
Following the first day of the event, Speakers, Sponsors, Press, Ultimate, Gold and Expo Plus attendees are invited to attend an evening of networking.
The Beach House will host the official networking party. It is located at the entrance of The Beach and surrounded by stunning beach scenery. Set away from the busier main structures and with its own bar and terrace. Discuss the topics from the conferences and build relationships with like-minded companies and individuals.
To register for your networking (Ultimate/ Gold/ Expo Plus) pass, click here.
The final advance rate ends 15 June so if you are looking for full conference and networking access, you can save up to €150 on your conference and networking pass (Gold/Ultimate) when you book by then.
You can find out more about the World Series 2018 and register for each event here:
AI Expo Europe – 27-28 th June 2018, RAI, Amsterdam
AI Expo North America – 28-29 th November 2018, Santa Clara, Silicon Valley
AI Expo Global – 25-26 th April 2019 , Olympia Grand, London
View source version on businesswire.com: https://www.businesswire.com/news/home/20180606006061/en/
Contact:
Anna Fry
Marketing Executive | AI Expo
anna@ai-expo.net
www.ai-expo.net/
+44
(0) 117 980 9020
Link:
Social Media:
https://www.facebook.com/aiexpoworldseries/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom